MIMaria A. Ilyushina

Maria A. Ilyushina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria A. Ilyushina has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mosaic Li–Fraumeni syndrome in acute lymphoblastic leukemia

    by A. N. Kazakova, V. A. Kozeev, K. R. Iliasova, D. S. Dzhumagazieva, A. S. Azatyan, Y. G. Abugova, M. A. Ilyushina, M. A. Klimentova, L. N. Shelikhova, E. Y. Osipova, et al.

    Li–Fraumeni syndrome (LFS) is a rare autosomal dominant tumor predisposition syndrome with high penetrance. The pathogenesis of the syndrome involves germline pathogenic variants in the TP53 gene. The spectrum of cancers in LFS predominantly includes solid tumors, with hematologic malignancies occurring in only 4% of cancer diagnoses. Most patients have a family history of the disease, however, in 10–20% of cases, germline variants are de novo. The introduction of next generation sequencing into clinical practice has made it possible to describe rare cases of mosaic LFS syndrome in some patients with solid tumors. This article presents the first described clinical case of mosaic LFS in a patient with hematologic malignancy. This case demonstrates how detailed molecular genetic testing using modern diagnostic techniques can determine the true origin of a pathogenic variant in the TP53 gene. The results of treatment show that, despite existing therapeutic options, patients with hematologic malignancies and LFS, including mosaic LFS, represent a challenging therapeutic group requiring the development of specialized treatment protocols.

  • Open Access

    Alpha/beta-T-cell depleted hematopoietic stem cell transplantation from unrelated and haploidentical donors in children with idiopathic aplastic anemia

    by Daria A. Shasheleva, L. N. Shelikhova, Maria A. Ilyushina, Rimma D. Khismatullina, A. A. Bogoyavlenskaya, Svetlana A. Radygina, E. E. Kurnikova, Dmitry E. Pershin, Dmitry N. Balashov, O. V. Goronkova, et al.

    Introduction. Hematopoietic stem cell transplantation (HSCT) from an alternative donor is the main treatment option for patients with severe acquired aplastic anemia (AAA) refractory to combined immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A. Although the outcomes of unrelated and haploidentical HSCTs have improved over the years, graft-versus-host disease (GVHD) continues to pose a major clinical challenge associated with significant morbidity and mortality. Aim: to present the outcomes of unrelated and haploidentical HSCTs with TCRαβ-depleted grafts in patients with AAA. Materials and methods. Eighty patients (42 males and 38 females) with AAA underwent HSCT between September 2012 and February 2022. The median age at transplantation was 10 (2.3–22.7) years. Seventy-eight patients received HSCT after relapse or refractory disease after one (n = 14) or two (n = 18) courses of immunosuppressive therapy. Two patients underwent HSCT as first-line treatment. The median time from diagnosis to transplantation was 1 (0.1–11.8) year. Conditioning regimen included cyclophosphamide (100–150 mg/kg), fludarabine (150 mg/kg), antithymocyte globulin (ATGAM (100 mg/kg) or thymoglobulin (5–10 mg/kg)), and thoracoabdominal irradiation (2–6 Gy). In some cases, additional medications such as melphalan (140 mg/m2), thiophosphamide (5–10 mg/kg), and rituximab (200 mg/m2) were used. Patients with paroxysmal nocturnal hemoglobinuria (n = 6) received eculizumab at a dose of 600 mg from day –7 to day +14 (every 7 days). Post-transplant GVHD prophylaxis included calcineurin inhibitors. TCRαβ/CD19 depletion was performed using a CliniMACS Plus system (Miltenyi Biotec, Bergish Gladbach, Germany). The median CD34+ cell dose in the graft was 10 (2.7–23.0) × 10⁶/kg, and the median TCRαβ+ cell dose was 26.6 (0.85–316.00) × 10³/kg. Results. The cumulative incidence of engraftment was 0,95 (95% confidence interval (CI) 0.9–1.0) with the median time to neutrophil recovery being 13 (9–24) days and to platelet recovery – 12 (7–25) days. Graft rejection occurred in 9 patients, the cumulative incidence of rejection was 0,11 (95% CI 0.06–0.20). Three of these patients underwent successful retransplantation. The cumulative incidence of grade II–III acute GVHD was 0,12 (95% CI 0.05–0.27) in the patients who had undergone unrelated donor HSCT versus 0,42 (95% CI 0.29–0.61) in the haploidentical HSCT recipients (p = 0.003). The cumulative incidence of chronic GVHD was 0,5 (95% CI 0.01–0.20) in the unrelated donor HSCT group and 0,21 (95% CI 0.12–0.38) in the haploidentical HSCT group (p = 0.02). The median follow-up was 6.4 years. Twenty-two (27.5%) patients died. Sixteen of them died of complications after the first HSCT; 4 deaths occurred due to complications associated with repeat HSCT. Two patients died after graft rejection due to infectious complications. The overall survival was 0,79 (95% CI 66–91) in the unrelated donor HSCT group and 0,66 (95% CI 51–81) in the haploidentical donor HSCT group. Conclusion. The use of TCRαβ/CD19-depleted HSCT from alternative donors ensured high engraftment rates and reduced the incidence of severe GVHD. However, there were no significant improvements in graft rejection or mortality.

  • Open Access

    Results of allogeneic hematopoietic stem cell transplantation from a genoidentical sibling after high-dose treosulfan-based conditioning in children with intermediate-risk acute myeloid leukemia in first clinical and hematological remission

    by Irina I. Kalinina, Larisa N. Shelihova, Maria A. Ilyushina, Gleb O. Bronin, Mikhail M. Antoshin, Elena V. Skorobogatova, Michael A. Maschan, Galina A. Novichkova, Alexey A. Maschan, Илюшина Мария Александровна

    The value of allogeneic hematopoietic stem cell transplantation (HSCT) in first remission in children with intermediate-risk acute myeloid leukemia (AML) remains the matter of debate. We analyze the outcome of HSCT from a genoidentical sibling with high-dose treosulfan-based myeloablative conditioning and enhanced graft-versus-host disease (GVHD) prophylaxis in comparison with continuation of high-dose chemotherapy (CT). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. A group of interest consisted of 22 HSCT recipients and a comparison group consisted of 240 patients who received high-dose CT. The conditioning regimens included treosulfan (n = 15), busulfan (n = 3), and melphalan (n = 4). The graft source was bone marrow in 12 patients and peripheral stem cells in 10 patients. GVHD prophylaxis was intensified either by including 1 or 2 additional immunosuppressive drugs or by increasing the duration of prophylaxis. The comparison group consisted of 240 patients who received 1 or 2 cycles of high-dose cytarabine- based consolidation therapy. The groups were matched for all initial characteristics. Engraftment was achieved in all 22 HSCT recipients: the median time to granulocyte recovery was day +16 (range, day +11 - day +21) and the median time to platelet recovery was day +15 (range, day +11 - day +28). The main toxicities of the conditioning regimens were mucositis in 12 (54%) patients, skin lesions in 6 (27%) patients, and an increase of alanine aminotransferase in 4 (18%) patients. There were no cases of toxicity-related mortality. Acute and chronic GVHD, requiring medical treatment developed in 15% of the patients. Four HSCT recipients relapsed between 3 months to 3 years after HSCT. In the high-dose CT group, 24 (10%) patients died of infectious complications and 79 (37%) patients developed a relapse. The cumulative incidence of relapse was 0.23 ± 0.10 and 0.44 ± 0.4 and the probability of the overall survival was 0.88 ± 0.08 and 0.83 ± 0.03 in the HSCT group and high-dose CT group, respectively (p 0.05). HSCT from a genoidentical sibling in intermediate-risk AML patients in first clinical and hematological remission is a safe and effective procedure, and tends to reduce the risk of AML relapse.

  • Open Access

    Identification of optimal conditions for the expansion of human bone marrow-derived mesenchymal stem cells using tools for live-cell culture monitoring

    by A. A. Dudorova, M. V. Efimenko, R. D. Khismatullina, M. A. Maschan, И. Н. Казьмина, M. A. Ilyushina, E. Yu. Osipova

    Based on the results of our study, we have developed recommendations regarding cell culture media composition for the expansion of human bone marrow-derived mesenchymal stem cells (MSC) for preclinical studies and potential clinical applications. ALPHA-MEM supplemented with 10% platelet lysate proved to be the most effective culture medium. Different DMEM media supplemented with fetal bovine serum turned out to be less effective: a maximum of 80% confluence was reached after 80 hours of culture, while MSC confluence in StemMACS and ALPHA-MEM media supplemented with platelet lysate kept increasing even after 100 hours of expansion. The growth rate of MSCs in RPMI-1640 medium was significantly lower than in the other culture media. When culturing MSCs in media with high glucose concentration (4.5 g/L), the percentage of cells with fat transformation after 5 days of culture was higher than in low-glucose (1.0 g/L) media such as DMEM low gl, StemMacs, ALPHAMEM. It is preferable to use MSC expansion media that do not induce spontaneous adipogenic differentiation for culturing MSCs for clinical purposes because the cells remain uncommitted and all their differentiation potential can be used in accordance with the objectives of further research and/or clinical needs. This study was supported by the local Ethics Committee and approved by the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. All the participants signed the standard informed consent form and agreed to the use of some of their biological materials for research purposes.

  • Open Access

    Allogeneic hematopoietic stem cell transplantation outcomes in pediatric patients with refractory acute myeloid leukemia

    by M. A. Ilyushina, L. N. Shelikhova, D. A. Shasheleva, M. A. Dunaykina, S. L. Blagov, E. E. Kurnikova, D. S. Pershin, I. I. Kalinina, Ya. O. Muzalevsky, A. S. Kazachenok, et al.

    Hematopoietic stem cell transplantation (HSCT) is known to be most effective in cancer patients in remission. In this paper, we analyzed a cohort of children with refractory acute myeloid leukemia (AML) in order to study the effectiveness of HSCT in such patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and was conducted in accordance with the principles of the Declaration of Helsinki. All the patients and/or their legal representatives signed an informed consent form for participation in the study. Our retrospective analysis included 69 patients with refractory AML (induction failure (n = 31), refractory relapse (n = 38)) whose median age was 9.4 (1.1–22) years and who had undergone HSCT between February 2012 and January 2020, with the median follow-up of 5.47 (1.9–8.9) years. Fifty patients were transplanted from haploidentical donors, 10 – from matched related donors, 9 – from matched unrelated donors. All the patients received treosulfan-based conditioning and either melphalan or thiotepa. Fifty-five cases received TCRab+/CD19+-depleted HSCs (CliniMACS), 11 patients received native bone marrow and 2 – unrelated umbilical cord blood. For post-transplant relapse prevention, 21 patients were treated with hypomethylating agents in combination with bortezomib and 48 patients received modified donor lymphocyte infusions. Primary engraftment was achieved in 66 out of 69 patients (3 patients had died before engraftment). By Day +30, 86% of patients showed complete chimerism. The cumulative incidence of grade II–IV acute graft-versus-host disease was 42%, chronic graft-versushost disease was diagnosed in 17 pts. In the entire cohort, transplant-related mortality was 7.8% and cumulative incidence of relapse was 53%. NK cell recovery by Day +30 was significantly associated with decreased incidence of relapse: patients whose absolute NK cell counts were below the median had a cumulative incidence of relapse of 76% versus 43% in patients with NK cell counts above the median (p = 0.013). At a median follow-up of 5.5 years, the event-free survival was 37 ± 11%, and the overall survival was 42 ± 10%. Remission was achieved in 86% of the patients, while long-term overall survival reached about 40%. Our findings suggest that allogeneic HSCT provides a reasonable chance of cure in children with refractory AML and creates a solid basis for further improvement. Tumor burden in the bone marrow before conditioning and early post-transplant NK cell counts in the blood were found to be the most significant prognostic factors in HSCT.


  • Open Access

    The results of therapy with venetoclax, daratumumab and plerixafor as part of the conditioning regimen in chemotherapy-refractory acute leukemia in children

    by Maria Klimentova, Лариса Шелихова, M. A. Ilushina, S. Blagov, M. E. Perminova, А. М. Попов, S. A. Kashpor, Maria Fadeeva, Yulia Olshanskaya, Svetlana Glushkova, et al.

    The main outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in chemotherapy-refractory acute leukemia remain suboptimal due to a high relapse rate. The incorporation of targeted anti-leukemia agents into the conditioning regimens is a potential approach to improve the efficacy of HSCT. We assessed the safety and potential efficacy of the addition of venetoclax, daratumumab, and plerixafor to the conditioning regimens in children with chemotherapy-refractory acute leukemias who received allogeneic TCRab/CD19-depleted HSCT. We used data from a pilot study, as well as the data of patients from a retrospective cohort who received similar therapy according to the individual indications. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All 43 patients (33 acute myeloid leukemias (AML), 8 T-cell acute lymphoblastic leukemias (T-ALL) and 2 acute leukemias of ambiguous lineage) had active disease status at the time of transplantation. The preparative regimen included myeloablative conditioning based on either total body irradiation or treosulfan or melphalan. A haploidentical related donor was used as a graft source in 38 cases, while a fully matched related or unrelated donor was used in 5 cases. The engraftment was observed in 93% of cases, no excessive toxicity was noted. MRD-negative complete remission was achieved in 37 patients (86%). The cumulative incidence of grade II–IV acute graft-versus-host disease (GvHD) was 10%, and the cumulative incidence of chronic GvHD was 5%. At 2 years, transplant-related mortality was 7%, relapse incidence was 52%, event-free survival was 41%, and overall survival was 51%. The overall survival rate for the AML group was 58% and 25% for the T-ALL group. Our data show that the addition of targeted agents to the conditioning regimens is safe, however, does not significantly improve the results of HSCT in the study cohort of patients.


  • Open Access

    Experience in the use of 5-azacytidine, bortezomib and valproic acid for the prevention of leukemia relapses in children after ab-T cell-depleted hematopoietic stem cell transplantation

    by M. A. Ilyushina, L. N. Shelikhova, D. A. Shasheleva, R. D. Khismatullina, S. L. Blagov, A. A. Maschan, M. A. Maschan

    Hematopoietic stem cell transplantation (HSCT) from an allogeneic donor is a standard treatment for high-risk leukemia that makes it possible to cure patients with chemotherapy-resistant leukemia. “Graft-versus-host” disease (GVHD) is the key biological and clinical problem associated with HSCT. Ex vivo depletion of ab-T cells has been used at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology since 2012 as a means to prevent GVHD after HSCT. The successful application of this approach to GVHD prevention has reduced the risk of clinically significant acute GVHD and chronic GVHD to 15–20 %, and transplant-related mortality – to 5–10 %. The risk of relapse is 20–30 %, but when HSCT is performed in active disease, it increases to 50 %. The role of epigenetic mechanisms in the formation of the tumor phenotype has been established, and pharmacological approaches have been proposed. New drug classes include proteasome inhibitors such as bortezomib. The relatively low toxicity of epigenetic therapy and proteasome inhibitors makes their use in the post-transplant period an attractive approach to relapse prevention. We regarded prophylaxis after HSCT as one of the possible approaches that could help reduce relapse rate. Here we explore the effects of hypomethylation therapy (azacitidine) combined with an HDAC inhibitor (valproic acid) and a proteasome inhibitor (bortezomib). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Combination therapy cycles were carried out after engraftment and in some patients, were accompanied by infusions of modified donor lymphocytes enriched in NK cells or memory T cells. The experimental group included 35 pediatric patients with hemoblastoses who had received HSCT from March 2013 to November 2016. The median age was 6.9 years. Twenty-three children had acute myeloid leukemia (AML), 11 patients – acute lymphoblastic leukemia (ALL), and one patient was diagnosed with juvenile myelomonocytic leukemia (JMML). Twenty-one patients were in complete clinical and hematologic remission at the time of HSCT while 14 patients (AML – 12, ALL – 1, JMML – 1) underwent HSCT in active disease. The patients were conditioned with treosulfan and melphalan (n = 26), thiotepa (n = 8), or etoposide (n = 1). Post-transplantation chemotherapy included azacitidine at a dose of 30 mg/m 2 IV for 5 days, bortezomib at a dose of 1.3 mg/m 2 s.c. (No. 2), and valproic acid at a dose of 250 mg 3 times a day р.о. (No. 6). The patients were planned to receive 3 cycles of post-transplantation chemotherapy with a break of 30 days between each treatment. Donor lymphocyte infusions were given on Day 7 of each cycle. A total of 92 cycles were conducted after HSCT. The most common side effect of treatment was hematologic toxicity. Transient visceral toxicity was registered after 46 (50 %) chemotherapy cycles. There were no cases of acute GVHD after donor lymphocyte infusions. At the time of the analysis, the median follow-up was 6.5 years. The cumulative risk of grade II–IV acute GVHD was 19% (95 % confidence interval (CI) 12–32). Nineteen patients relapsed at a median of 6 months after HSCT. Sixteen patients died of disease progression or complications related to subsequent treatment at a median of 11.76 months. The cumulative probability of relapse was 54% (95% CI 40–73). The cumulative probability of relapse in the patients transplanted in clinical and hematologic remission and those in active disease was 48% (95% CI 30–75) and 64 % (95 % CI 43–95), respectively. The event-free survival in the entire group of patients was 46 % (95 % CI 29–62). The event-free survival rates in the patients transplanted in remission and in active disease were 52% (95% CI 31–73) and 36 % (95 % CI 10–60), respectively. There were no deaths of complications of HSCT that were not associated with the recurrence of the disease in the experimental group. The cumulative risk of relapse among the AML patients in clinical and hematologic remission at the time of HSCT and those with advanced stage of the disease was 45 % (95 % CI 40–74) and 58 % (95 % CI 36–94), respectively. The overall survival was 53 % (95 % CI 31–73); the overall survival for the patients transplanted in remission and those who received HSCT in active disease was 63% (95 % CI 35–92) and 41% (95% CI 14–70), respectively. The event-free survival was 54% (95% CI 30–62) in the remission group and 41% (95 % CI 14–69) in the relapse group. In the ALL patients, the cumulative risk of relapse was 54 % (95 % CI 31–93); the overall and event-free survival rates were 72 % (95 % CI 46–91) and 45 % (95 % CI 16–75), respectively. Our analysis of the overall experience of prophylactic treatment with decitabine and azacitidine after ab-T cell-depleted HSCT suggests that this approach should be considered purely experimental and acceptable for prospective clinical studies in clearly defined cohorts of patients.


  • MINI-PHOTOPHERESIS – A NON-LEUKAPHERESIS BASED EXTRACORPOREAL PHOTOPHERESIS: CLINICAL EXPERIENCE

    by I.B. Kumukova, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, E.E. Kurnikova, M.A. Ilyushina, P.E. Trakhtman

    Extracorporeal photopheresis (ECP) has proven effectiveness for treatment of several diseases, including acute and chronic graft-versus-host disease (GVHD) after allogenic transplantation of hematopoietic blood stem cells. The standard ECP requires leukapheresis to obtain a mononuclear cell fraction. The possibility of using leukapheresis is limited by the requirements for vascular access and the somatic status of the patient. There is a relatively new method of performing ECF, called «mini-photopheresis» (mini-ECF), in which a fraction of mononuclear cells is isolated from a dose of whole blood obtained by the exfusion method. The article presents preliminary results of using mini-ECP in patients with acute and chronic GVHD. Materials and methods of research: the study included 11 patients with acute (7 patients) and chronic (4 patients) GVHD who received mini-ECP therapy from June 2018 to January 2021. Leukocyte fractions rich in mononuclear cells were prepared from the dose of whole blood of patients. The resulting fraction was diluted with 0,9% NaCl solution to less than 3% hematocrit. The cellular product was then injected with an 8-Methoxyperalene and programmed with UV spectrum A. Autologous erythrocytes and the finished cellular product were injected into the patient after irradiation. Results: 6 out of 7 patients (85,7%) with acute GVHD has responded to mini-ECP therapy. In patients with chronic GVHD, the response rate to mini-ECP therapy was 25%. In both groups there are no significant differences found in the number of leukocytes count per body mass in the finished cellular product. The correlation between the presence and severity of response to mini-ECP therapy with the number of leukocytes in the finished cellular product was not determined. None of the patients had adverse reactions and complications associated with mini-ECP therapy. Conclusion: mini-ECP is an attractive alternative for treatment of patients with steroid-resistant or steroid-dependent GVHD who cannot undergo leukapheresis. Our results are preliminary, but promising. We will continue to use this method as a second-line therapy for patients with contraindications to leukapheresis.


  • Open Access

    αβ-T-cell-depleted haploidentical hematopoietic stem cell transplantation in children with chemorefractory acute myeloid leukemia

    by L. N. Shelikhova, M. A. Ilushina, K. V. Semiglazova, Zh. B. Shekhovtsova, D. A. Shasheleva, R. D. Khismatullina, E. E. Kurnikova, D. S. Pershin, D. N. Balashov, S. A. Radygina, et al.

    Primary refractory and relapsed refractory acute myeloid leukemia remains an unresolved problem in pediatric oncology. Children with AML who fail to achieve complete remission on high-dose cytarabine and antracyclines have no chance for survival without allogeneic hematopoietic stem cell transplantation. We evaluated the outcome of αβ-T-cell-depleted haploidentical transplantation in a cohort of children with chemorefractory acute myeloid leukemia. Thirty-six patients with either primary refractory (n = 14) or relapsed refractory (n = 22) acute myeloid leukemia in active disease status received a transplantation from haploidentical donors. The preparative regimen included cytoreduction with fludarabine and cytarabine and subsequent treatment with treosulfan and either melphalan or thiophosphamide. Serotherapy consisted of antithymocyte globuline in 14 pts and targeted immunomodulation with tocilizumab +/- abatacept in 22 pts. Grafts were PBSCs engineered by TCR-αβ/CD19 depletion. Posttransplant preemptive therapy included modified donor lymphocyte infusions with or without hypomethylating agents. Complete remission was achieved in 30 (83%) рts. The cumulative incidence of acute GVHD grade II–IV was 25%, and the cumulative incidence of chronic GVHD was 18%. Transplant-related mortality was 6%, and relapse incidence was 48%. Event-free survival was 46%, and overall survival was 41% at 2 years. Good early recovery of NK cells was associated with significantly improved survival and decreased relapse incidence. Our data suggest that αβ-T-cell-depleted haploidentical HSCT provides a reasonable chance of cure in a cohort of children with chemorefractory acute myeloid leukemia and creates a solid basis for further improvement. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology.


  • Open Access

    The Influence of Natural Killer Cell Alloreactivity on the Outcome of α/βTCR/CD19+ depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Leukemia

    by V. V. Zakharova, Z. B. Shekhovtsova, O. A. Shragina, E. V. Raykina, M. A. Ilushina, Y. O. Muzalevskii, A. G. Kochetov, L. N. Shelikhova, M. A. Maschan